Viking Therapeutics
VKTX
375 hedge funds and large institutions have $6.56B invested in Viking Therapeutics in 2024 Q1 according to their latest regulatory filings, with 203 funds opening new positions, 78 increasing their positions, 87 reducing their positions, and 25 closing their positions.
712% more first-time investments, than exits
New positions opened: 203 | Existing positions closed: 25
550% more funds holding in top 10
Funds holding in top 10: 2 → 13 (+11)
353% more capital invested
Capital invested by funds: $1.45B → $6.56B (+$5.11B)
90% more funds holding
Funds holding: 197 → 375 (+178)
47% more call options, than puts
Call options by funds: $730M | Put options by funds: $496M
4.66% less ownership
Funds ownership: 77.91% → 73.25% (-4.7%)
10% less repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 87
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$160M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$107M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$59.8M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$46.2M |
| 5 |
PA
Perceptive Advisors
New York
|
+$44.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$180M |
| 2 |
State Street
Boston,
Massachusetts
|
-$107M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$95M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$94M |
| 5 |
Morgan Stanley
New York
|
-$90.2M |
VKTX Hedge Fund Activity: Q1 2024 in Review
375 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q1 2024, worth a combined $6.56B — up 353% from $1.45B a quarter earlier.
Buyers outnumbered sellers: 203 funds opened new VKTX positions and 25 closed out — a net gain of 178 holders — while 78 added to existing stakes and 87 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $160M. The largest seller was Viking Global Investors, cutting an estimated $180M.
- 375 institutional investors held Viking Therapeutics (VKTX) as of Q1 2024, up from 197 in Q4 2023.
- Funds reported $6.56B of Viking Therapeutics stock for Q1 2024, up 353% quarter-over-quarter.
- 203 funds opened new Viking Therapeutics positions in Q1 2024 and 25 closed out, a net change of +178 holders.
- The largest Viking Therapeutics buyer in Q1 2024 was Avoro Capital Advisors, an estimated $160M added.
- The largest Viking Therapeutics seller in Q1 2024 was Viking Global Investors, an estimated $180M sold.
Based on aggregated 13F filings for Q1 2024.